Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin D for Epistaxis in Hereditary Haemorrhagic Telangiectasia
NCT03981562Phase 2Unknown
- Sponsor
- St. Paul's Hospital
- Start
- Jul 2018
- Primary completion
- Jul 2020
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vitamin d in hereditary hemorrhagic telangiectasia (HHT), sponsored by St. Paul's Hospital. Primary endpoint: Epistaxis Severity Score at 6 months. Status: unknown.
02
Drugs
vitamin d
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NCT03981562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03981562.